A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination with Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients with Pancreatic Cancer

Go Back to All Clinical Trials

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination with Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients with Pancreatic Cancer

Brief description of study

Single Arm Phase Ib study at fixed dose of standard of care chemotherapy and anti PD1 and IL1b to evaluate the safety and preliminary toxicity of this quadruplet regimen prior to resection for pancreatic cancer.

Clinical Study Identifier: s22-01205

ClinicalTrials.gov Identifier: NCT05984602

Principal Investigator: Paul E. Oberstein.

Other Investigators: Diane Simeone, Daniel J Becker, Kristen Spencer, Nina Beri, Jennifer Chuy, Rafael Winograd, Shun Yu.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies